Scientists question cancer tests that use microscopic nematode worms


Light micrograph of Caenorhabditis elegans.

The worm Caenorhabditis elegans, a lab stalwart, is main to a Japanese business’s cancer-screening test. Credit: Sinclair Stammers/Science Photo Library

Questions have actually been raised about the precision of a test offered by a Japanese start-up business that is developed to discover an individual’s danger of specific kinds of cancer from a urine sample. 2 Japanese medical societies have actually introduced an examination following issues voiced by numerous physicians about the precision of the tests, which count on the motion of tiny nematode worms to discover the existence of tumours.

The test, called N-NOSE, is produced by Hirotsu Bio Science, based in Tokyo. The business states its test can discover 15 kinds of cancer, consisting of breast, oesophageal, stomach and prostate cancers. The tests, at an expense of ¥ 14,800 (about US$ 100) each, have actually been on the marketplace in Japan because 2020. The business advises individuals whose outcomes put them at the greatest danger of cancer to look for professional recommendations; up until now, about 5% of the 500,000 individuals who have actually been evaluated have actually remained in this classification.

The test utilizes an exclusive algorithm to examine whether nematode worms have actually moved towards a urine sample in a meal. The concept for it concerned the president of Hirotsu Bio Science, Takaaki Hirotsu, following reports1 that the larvae of the nematode worm Anisakis simplex was drawn in to swallow tumours. He questioned whether the lab stalwart Caenorhabditis elegans, which has a a great deal of olfactory receptors, may be drawn in to cancer– and whether determining the motion of the worms towards a tumour or towards the chemicals that a tumour releases might be utilized for medical diagnosis. His group’s 2015 observation2 that C. elegans is drawn in to urine samples from individuals with cancer has actually been confirmed in breast cancer and prostate cancer by independent research study groups in Italy3 and the United States4, respectively. Both groups kept in mind that the result depends on the particular conditions of the test and that, under some conditions, it is not observed.

In a 2021 paper5, the group behind N-NOSE provided outcomes revealing that the commercially offered test has a level of sensitivity of around 87%, suggesting that of 100 individuals with cancer, 87 will be gotten by the test. They estimate an uniqueness of 90%, suggesting that of 100 individuals without cancer, 90 would get an N-NOSE outcome suggesting they’re at low danger.

A delicate concern

But numerous physicians have actually queried these figures, recommending there are greater levels of both incorrect negatives and incorrect positives in individuals utilizing the tests.

At a cancer detection and medical diagnosis conference in Fukuoka in June, Kuniyuki Tashiro, a medical professional at the Fukuoka Wajiro Positron Emission Tomography (PET) Imaging Diagnostic Clinic, informed a session devoted to nematode screening that of 333 individuals who took the N-NOSE test and got outcomes suggesting they were high-risk, simply 8 had cancer– and 2 of those cancers were a type that N-NOSE does not declare to discover. Yoichi Mizutani, a medical professional at Nishinokyo Hospital in Nara, states that of 28 individuals flagged as high danger by N-NOSE, not one had cancer. Seigo Fujita, a medical professional and director of a cancer centre at Miyazaki Tsuruta Memorial Clinic in Miyazaki City, Japan, explained how he had actually seen 10 individuals who had actually been detected with cancer who all got N-NOSE outcomes explaining their cancer danger as low.

On the back of these issues, radiologists associated with PET screening for the Japanese Association for Cancer Detection and Diagnosis in Tokyo have actually accompanied a working group of the PET Nuclear Medicine Subcommittee of the Japanese Society of Nuclear Medicine in Tokyo to introduce a study into the item. They have actually asked member centers to supply details on the number of clients have actually had a PET scan for cancer due to the fact that of an N-NOSE test outcome, and what their PET screening results became.

A declaration supplied to Nature by Hirotsu Bio Science in reaction to the medical societies’ study states that PET screening is not ideal for the early detection of cancer for which N-NOSE is meant. The study “can not supply a trustworthy confirmation” of the N-NOSE innovation, the business states.

Hirotsu Bio Science President Takaaki Hirotsu demonstrates the N-Nose system for early-stage pancreatic cancer screening in Tokyo in 2021.

Takaaki Hirotsu is the creator of Hirotsu Bio Science, the business behind the N-NOSE cancer-screening test. Credit: Yoshikazu Tsuno/Gamma-Rapho by means of Getty

The business likewise has prepare for growth. At an interview likewise in June, Hirotsu signed a memorandum of comprehending with the Global Health Equity Fund, a mutual fund supported by the WHO Foundation in Geneva, Switzerland– a charity connected with the World Health Organization– and Israeli venture-capital company OurCrowd in Jerusalem. The business has actually likewise provided its research study to the World Economic Forum in Davos, Switzerland, and to the Science and Technology in Society online forum in Kyoto, a significant conference of international researchers and policymakers. The business is offering N-NOSE in China and prepares to introduce in the United States next year.

The business’s primary innovation officer, Eric di Luccio, informed Nature that the criticisms raised by the physicians are “100% bullshit”.

He referred Nature to an analysis prepared by the business of the figures that the physicians provided. The analysis and accompanying declaration states that the issues raised by physicians have actually not gone through peer evaluation, unlike much of the figures provided by the business, which appear in released documents. The declaration acknowledges that the test is not 100% precise– really couple of tests are– however states that the business “will continue to actively perform joint research study with other organizations and make every effort to accomplish even greater precision”. It mentions that N-NOSE does not intend to identify, just to supply assistance on danger levels.

” This is a brand-new innovation and it requires time and effort to make individuals comprehend it,” di Luccio states.

But when it pertains to cancer, both incorrect negatives and incorrect positives can trigger damage. The issues require to be examined, states Yuji Yamada, a Japanese geriatrician at Icahn School of Medicine at Mount Sinai, New York City. Individuals who get incorrect positives may go on to have unneeded biopsies, or scans that expose them to radiation. And if N-NOSE outcomes are unfavorable when somebody in fact has cancer, detection may be postponed, reducing the possibility of survival.

The outcomes of the examination by the Japanese medical societies is anticipated to be released early next year.


Please enter your comment!
Please enter your name here